GlobeNewswire
BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting
📈
AI Sentiment
Highly Positive
8/10
- Home
- BTAI
as of 01-22-2026 11:09am EST
$1.82
$0.03
-1.36%
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 43.7M | IPO Year: | 2018 |
| Target Price: | $26.67 | AVG Volume (30 days): | 644.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.17 - $8.08 | Next Earning Date: | 11-12-2025 |
| Revenue: | $752,000 | Revenue Growth: | -66.96% |
| Revenue Growth (this year): | -74.18% | Revenue Growth (next year): | 265.60% |
Latest BioXcel Therapeutics Inc. News
BTAI Breaking Stock News: Dive into BTAI Ticker-Specific Updates for Smart Investing
Compare BTAI vs Leading Stocks
See how BTAI stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BTAI BioXcel Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.